Immunostimulatory oligoribonucleotides
View Patent ↗The invention provides immunostimulatory compositions and use of those compounds in the preparation of medicaments for the treatment of disease as well as in vitro uses. In particular, the compositions of the invention include immunostimulatory oligoribonucleotides that incorporate a sequence-dependent immunostimulatory sequence motif. Specific modifications involving phosphate linkages, nucleotide analogs, adducts, and combinations thereof are provided. Compositions of the invention, which optionally can include an antigen, can be used alone or together with other treatments to stimulate or enhance an immune response. Also provided are compositions and methods useful for treating a subject having an infection, a cancer, an allergic condition, asthma, airway remodeling, or immunodeficiency. Immunostimulatory oligoribonucleotides of the invention are believed to stimulate Toll-like receptor 8 (TLR8).
1. An oligoribonucleotide consisting of UUAUUAUUAUUAUUAUUAUU (SEQ ID NO: 13), wherein the oligoribonucleotide includes at least one backbone modification.
2. The oligoribonucleotide of claim 1 , wherein the oligoribonucleotide is complexed to N-[1-(2,3-Dioleoyioxy)propyl],N,N,N-trimethylammonium methyl sulfate to form a conjugate.
3. The oligoribonucleotide of claim 1 , wherein the backbone comprises internucleoside phosphorothioate linkages between each nucleotide.
4. The oligoribonucleotide of claim 1 , wherein the oligoribonucleotide is separated from 5′ ribonucleotide by a non-nucleotide linker.
5. The oligoribonucleotide of claim 1 , wherein the oligoribonucleotide is separated from a 3′ ribonucleotide by a non-nucleotide linker.
6. The oligoribonucleotide of claim 1 , wherein the oligoribonucleotide is separated from a 5′ arid 3′ ribonucleotide by a non-nucleotide linker.
7. A composition comprising an oligoribonucleotide consisting of UUAUUAUUAUUAUUAUUAUU (SEQ ID NO: 13) in a delivery vehicle, wherein said oligoribonucleotide includes at least one backbone modification; and optionally non-nucleotidic linkers; and optionally a) a lipophilic moiety, b) a CpG motif, c) an antigen, d) an adjuvant, and e) a pharmaceutically acceptable carrier.
8. The composition of claim 7 wherein the delivery vehicle is N-[1-(2,3-Dioleoyloxy)propyl 1-N,N,N-trimethylammonium methyl-sulfate.
9. The composition of claim 7 further comprising a lipophilic moiety.
10. The composition of claim 8 wherein the lipohilic moiety and the oligoribonucleotide are conjugated.
11. The composition of claim 7 further comprising a CpG motif.
12. The composition of claim 7 further comprising an antigen.
13. The composition of claim 7 further comprising an adjuvant.
14. The composition of claim 7 further comprising a pharmaceutically acceptable carrier.